

IND SAFETY REPORT: INITIAL WRITTEN REPORT**TO: Division of Drug Oncology Products, Center for Drug Evaluation and Research, FDA****FAX: 301-796-9845**

1. IND NUMBER

63383

2. AGENT NAME

OSI-774 (erlotinib; Tarceva)

3. DATE

March 11, 2009

4. SPONSOR

Division of Cancer Treatment and Diagnosis, National Cancer Institute

5. REPORTER'S NAME, TITLE, AND INSTITUTION

Helen Chen, MD-Associate Branch Chief for Investigational Therapeutics 3, CTEP, DCTD, NCI

6. PHONE NUMBER

301-496-1196

7. FAX NUMBER

301-402-0428

8. PROTOCOL NUMBER (AE #)

CALGB-30406 (AE# 1225018)

9. PATIENT IDENTIFICATION

114320

10. AGE

69

11. SEX

Female

12. DESCRIPTION OF ADVERSE EVENT

The patient was a 69-year-old female with non-small cell lung cancer who died from renal failure while on a phase 2 trial utilizing the investigational agent erlotinib in combination with carboplatin and paclitaxel. She began the investigational therapy on January 22, 2009, and received her last dose of erlotinib on January 27, 2009 (Cycle 1, Day 6), and the last doses of carboplatin and paclitaxel on January 22, 2009 (Cycle 1, Day 1). On January 27, 2009, the patient presented to the clinic with vomiting and a several day history of diarrhea. Her BUN was 52 mg/dL (reference range 6-19 mg/dL) and her creatinine level was 1.2 mg/dL (reference range 0.5-1.0). Erlotinib was put on hold and she was admitted to the hospital for dehydration and renal insufficiency. After receiving IV fluids and loperamide, her renal function was normal until January 30, 2009, at which time, she developed shortness of breath, and her creatinine increased to 2.0 mg/dL. She was transferred to the intensive care unit and given antibiotics and sodium bicarbonate for metabolic acidosis. Fecal cultures were negative for enteropathogens and *Clostridium difficile*, and blood cultures were also negative. Her urine output continued to decline and her creatinine level continued to increase. The patient elected DNR status and on February 13, 2009, was put on comfort care. She expired on February 17, 2009. No autopsy was performed. Additional information has been requested from the investigational site. There is a reasonable possibility that the experience may have been caused by the drug.

13. DOSE, ROUTE, AND SCHEDULE

Cycle =21 Days**Erlotinib 150 mg PO QD**

14. DATES OF TREATMENT

The patient began the investigational therapy on January 22, 2009, and received the last dose of erlotinib on January 27, 2009 (Cycle 1, Day 6).

15. ACCRUAL AND IND EXPERIENCE

Number of patients enrolled in NCI-sponsored clinical trials using erlotinib = 2749. There have been 9 other incidences of renal failure reported to the NCI through AdEERS as serious adverse events for erlotinib

16. COMMENTS

The following was also administered on Cycles 1-6:**Carboplatin AUC 6 IV over 15-30 minutes on Day 1; Last administered on January 22, 2009.****Paclitaxel 200 mg/m² IV over 3 hours on Day 1, Cycle 1, and IV over 1-3 hours on Day 1 of subsequent cycles; Last administered on January 22, 2009.****AT THIS TIME, NO OTHER INFORMATION IS AVAILABLE. IF UPON FURTHER INVESTIGATION RELEVANT INFORMATION BECOMES AVAILABLE, THEN A FOLLOW-UP REPORT WILL BE SUBMITTED IN ACCORDANCE WITH 21CFR312.32(d)(2).****DISCLAIMER per 21 CFR 312.32(e): THIS SAFETY REPORT DOES NOT NECESSARILY REFLECT A CONCLUSION OR ADMISSION BY THE CTEP IDB SENIOR INVESTIGATOR/ SPONSOR THAT THE INVESTIGATIONAL AGENT/THERAPY CAUSED OR CONTRIBUTED TO THE ADVERSE EXPERIENCE BEING REPORTED.**

0002